Evidence map›Paper›PMID 25225802›Full record

ArticlePloS one2014

A field evaluation of the Hardy TB MODS Kit™ for the rapid phenotypic diagnosis of tuberculosis and multi-drug resistant tuberculosis.

Laura Martin, Jorge Coronel, Dunia Faulx, Melissa Valdez, Mutsumi Metzler, Chris Crudder, Edith Castillo, Luz Caviedes, Louis Grandjean, Mitzi Rodriguez and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Pooled it
  2. Article
  3. Article
  4. The 2021 WHO catalogue ofThe Lancet. Microbe · 2022
    Article
  5. Article
  6. Article
  7. Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2017
    Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Laura MartinLaboratorio de Investigación en Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru; Wellcome Centre for Clinical Tropical Medicine, Imperial College of Science, Technology and Medicine, London, United Kingdom.
Jorge CoronelLaboratorio de Investigación en Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru.
Dunia FaulxPATH, Seattle, Washington, United States of America.
Melissa ValdezPATH, Seattle, Washington, United States of America.
Mutsumi MetzlerPATH, Seattle, Washington, United States of America.
Chris CrudderPATH, Seattle, Washington, United States of America.
Edith CastilloLaboratorio de Salud Pública de la Dirección Regional de Salud del Callao, Lima, Peru.
Luz CaviedesLaboratorio de Investigación en Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru.
Louis GrandjeanLaboratorio de Investigación en Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru; Wellcome Centre for Clinical Tropical Medicine, Imperial College of Science, Technology and Medicine, London, United Kingdom.
Mitzi RodriguezLaboratorio de Salud Pública de la Dirección Regional de Salud del Callao, Lima, Peru.
Jon S FriedlandWellcome Centre for Clinical Tropical Medicine, Imperial College of Science, Technology and Medicine, London, United Kingdom.
Robert H GilmanLaboratorio de Investigación en Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
David A J MooreLaboratorio de Investigación en Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America; TB Centre and Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Program for Appropriate Technology in Health · USUniversidad Peruana Cayetano Heredia · PEDirección Regional de Salud del Callao · PEImperial College London · GBJohns Hopkins University · USLondon School of Hygiene & Tropical Medicine · GB

Funding

Medical Research Council MR/K007467/1Wellcome TrustWellcome Trust 078067/Z/05/Z
6 · The paper itself

Abstract

backgroundEven though the WHO-endorsed, non-commercial MODS assay offers rapid, reliable TB liquid culture and phenotypic drug susceptibility testing (DST) at lower cost than any other diagnostic, uptake has been patchy. In part this reflects misperceptions about in-house assay quality assurance, but user convenience of one-stop procurement is also important. A commercial MODS kit was developed by Hardy Diagnostics (Santa Maria, CA, USA) with PATH (Seattle, WA, USA) to facilitate procurement, simplify procedures through readymade media, and enhance safety with a sealing silicone plate lid. Here we report the results from a large-scale field evaluation of the MODS kit in a government service laboratory. METHODS &

findings2446 sputum samples were cultured in parallel in Lowenstein-Jensen (LJ), conventional MODS and in the MODS kit. MODS kit DST was compared with conventional MODS (direct) DST and proportion method (indirect) DST. 778 samples (31.8%) were Mycobacterium tuberculosis culture-positive. Compared to conventional MODS the sensitivity, specificity, positive, and negative predictive values (95% confidence intervals) of the MODS Kit were 99.3% (98.3-99.8%), 98.3% (97.5-98.8%), 95.8% (94.0-97.1%), and 99.7% (99.3-99.9%). Median (interquartile ranges) time to culture-positivity (and rifampicin and isoniazid DST) was 10 (9-13) days for conventional MODS and 8.5 (7-11) for MODS Kit (p<0.01). Direct rifampicin and isoniazid DST in MODS kit was almost universally concordant with conventional MODS (97.9% agreement, 665/679 evaluable samples) and reference indirect DST (97.9% agreement, 687/702 evaluable samples).

conclusionsMODS kit delivers performance indistinguishable from conventional MODS and offers a convenient, affordable alternative with enhanced safety from the sealing silicone lid. The availability in the marketplace of this platform, which conforms to European standards (CE-marked), readily repurposed for second-line DST in the near future, provides a fresh opportunity for improving equity of access to TB diagnosis and first and second-line DST in settings where the need is greatest.

Indexed as

Mycobacterium tuberculosisReagent Kits, DiagnosticAntitubercular AgentsHumansIsoniazidMicrobial Sensitivity TestsPeruReproducibility of ResultsRifampinSensitivity and SpecificitySputumTuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsIsoniazidReagent Kits, DiagnosticRifampin

Identifiers

PMID25225802
PMCPMC4167337
OpenAlexW2129487647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.